Table 2.

Comparison of safety and efficacy outcomes between bevacizumab biosimilar and reference bevacizumab.

Outcome Measure	Bevacizumab Biosimilar Cohort	Reference Bevacizumab Cohort
Overall Response Rate (ORR)	50.0% (95% CI: 45.0-55.0)	48.0% (95% CI: 43.0-53.0)
Progression-Free Survival (PFS)	7.5 months (95% CI: 7.0-8.0)	7.2 months (95% CI: 6.7-7.7)
Overall Survival (OS)	18.0 months (95% CI: 16.0-20.0)	17.5 months (95% CI: 16.0-19.0)

The Overall Response Rate (ORR) is presented as a percentage with the 95% confidence interval (CI) in parentheses.

Decimal places are consistently retained across the table to ensure clarity and accuracy.